Elevation Oncology (NASDAQ:ELEV – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Volatility & Risk Elevation Oncology has […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 1,320,000 shares, a drop of 11.4% from the June 30th total of 1,490,000 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio […]
BML Capital Management LLC bought a new position in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 39,963 shares of the company’s stock, valued at approximately $38,000. Elevation Oncology accounts for 0.0% […]
SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report issued on Tuesday, The Fly reports. SVB Securities currently has $8.00 target price on the stock, up from their previous target price of $5.00. Separately, Wedbush reiterated an outperform rating and set […]
SVB Leerink upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a research report report published on Tuesday morning, PriceTargets.com reports. A number of other analysts have also recently issued reports on ELEV. Wedbush restated an outperform rating and set a $4.00 price objective on […]